Cancer

Title
The Effects, Good and/or Bad, of Adding Abiraterone and Prednisone to Enzalutamide in Men with Prostate Cancer that has Spread and has not Responded to Hormonal Therapy.
Trial Number
206142021914
Number of Participants
1,224
Principal Investigator

Elizabeth Henry

M.D.
Hematology/Oncology
Assistant Professor
Eligibility

Adult men with progressive castration-resistant metastatic prostate cancer who have not had treatment with prior taxane-based chemotherapy for their metastatic disease. They must not have any clinically significant cardiovascular disease or other major co-morbidities and have a PS 0-1.

Purpose

The purpose of this study is to compare the effects, good and/or bad, of abiraterone, prednisone and enzalutamide with enzalutamide alone on you and your prostate cancer to find out which is better. Doctors are uncertain about what is the best way to treat castration-resistant prostate cancer.

Enrollment

(708) 327-3153

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.